Home Cart 0 Sign in  
X

[ CAS No. 14548-38-0 ]

{[proInfo.proName]} ,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 14548-38-0
Chemical Structure| 14548-38-0
Chemical Structure| 14548-38-0
Structure of 14548-38-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Bulk Inquiry Add To Cart

Quality Control of [ 14548-38-0 ]

Related Doc. of [ 14548-38-0 ]

Alternatived Products of [ 14548-38-0 ]

Product Details of [ 14548-38-0 ]

CAS No. :14548-38-0 MDL No. :MFCD00956388
Formula : C9H7ClO Boiling Point : -
Linear Structure Formula :- InChI Key :SMSGJDOJSQHQIW-UHFFFAOYSA-N
M.W :166.60 Pubchem ID :5100705
Synonyms :

Calculated chemistry of [ 14548-38-0 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.22
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 0.0
Molar Refractivity : 44.5
TPSA : 17.07 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.69 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.93
Log Po/w (XLOGP3) : 2.29
Log Po/w (WLOGP) : 2.47
Log Po/w (MLOGP) : 2.28
Log Po/w (SILICOS-IT) : 3.4
Consensus Log Po/w : 2.47

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 2.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.72
Solubility : 0.318 mg/ml ; 0.00191 mol/l
Class : Soluble
Log S (Ali) : -2.29
Solubility : 0.862 mg/ml ; 0.00518 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.72
Solubility : 0.0315 mg/ml ; 0.000189 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.51

Safety of [ 14548-38-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P273 UN#:N/A
Hazard Statements:H302-H412 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 14548-38-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 14548-38-0 ]
  • Downstream synthetic route of [ 14548-38-0 ]

[ 14548-38-0 ] Synthesis Path-Upstream   1~22

  • 1
  • [ 107-94-8 ]
  • [ 108-90-7 ]
  • [ 15115-59-0 ]
  • [ 14548-38-0 ]
Reference: [1] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 16, p. 687
[2] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 16, p. 687
  • 2
  • [ 107-94-8 ]
  • [ 7446-70-0 ]
  • [ 108-90-7 ]
  • [ 15115-59-0 ]
  • [ 14548-38-0 ]
Reference: [1] Patent: US1754031, 1927, ,
[2] Patent: US1754031, 1927, ,
[3] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 16, p. 687
  • 3
  • [ 2019-34-3 ]
  • [ 14548-38-0 ]
YieldReaction ConditionsOperation in experiment
100% With trifluorormethanesulfonic acid In dichloromethane at 80℃; for 1 h; High pressure; Inert atmosphere; Green chemistry General procedure: Trifluoromethane sulfonic acid (3 eq.) was gently added to a cooled (0 °C) solution of a 3-Phenylpropionic acid (0.5 mmol) in dry CH2Cl2 (1.0 mL) in a 12 mL Q-tube™ pressure tube, furnished by QLabtech. The temperature was raised to room temperature. A Teflon septum was placed on the top of the tube and the appropriate cap and pressure adapter were used. The mixture was heated in an oil bath at 80 °C. The reaction was monitored by TLC and GC/MS until the reactant disappeared. The mixture was poured into ice and extracted three times with CH2Cl2. The organic phase collected was dried on Na2SO4, filtered and concentrated under vacuum. The desired pure product was separated from the crude by flash chromatography.
66%
Stage #1: With oxalyl dichloride In dichloromethane for 8 h;
Stage #2: With aluminum (III) chloride In dichloromethane for 6 h; Reflux
To a stirred solution of 4-chlorocinnamic acid (1.0g, 5.46mmol) in EtOAc (20mL) was added Pd on carbon (0.12g, 0.11mmol) at room temperature under H2atmosphere. The mixture was stirred for 10h. The resulting mixture was filtered through celite and the solvent of the filtrate was removed in vacuo. The concentrated product was employed without further purification in the next reaction. Oxalyl chloride (0.96mL, 10.92mmol) was cautiously added to a solution of the 3-(4-chlorophenyl)propanoic acid in CH2Cl2(20mL). The mixture was stirred for 8h and then the solvent was removed vacuo. The appropriate acid chloride was employed without further workup in the next reaction step. To a stirred solution of acid chloride in CH2Cl2(20mL) was added portionwise AlCl3(0.82g, 6.22mmol) at room temperature and heated under reflux for 6h. The resulting mixture was poured into ice-water and the aq. phase was extracted with CH2Cl2,washed with 1N aq. NaOH and brine, dried over MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to produce the title compound (0.59 g, 66 percent).1H NMR (400 MHz, CDCl3) δ 2.64-2.78 (m, 2H), 3.04-3.17 (m, 2H), 7.41 (d,J=7.9, 1H), 7.55 (dd,J=8.2, 1H), 7.65-7.75 (m, 1H).
Reference: [1] Molecules, 2014, vol. 19, # 5, p. 5599 - 5610
[2] Patent: WO2017/150904, 2017, A1, . Location in patent: Paragraph 402-404
[3] Synthetic Communications, 2007, vol. 37, # 13, p. 2171 - 2177
[4] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 8, p. 2554 - 2558
[5] Polish Journal of Chemistry, 1991, vol. 65, # 11, p. 2057 - 2060
[6] European Journal of Medicinal Chemistry, 1976, vol. 11, # 1, p. 83 - 88
[7] Chemische Berichte, 1969, vol. 102, p. 3656 - 3665
[8] Journal of Medicinal Chemistry, 1972, vol. 15, p. 341 - 344
[9] Archiv der Pharmazie, 1975, vol. 308, # 2, p. 94 - 109
[10] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1999, vol. 38, # 4, p. 407 - 412
[11] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 5, p. 1333 - 1336
[12] Journal of Medicinal Chemistry, 2003, vol. 46, # 3, p. 399 - 408
[13] Letters in Drug Design and Discovery, 2014, vol. 11, # 5, p. 578 - 585
[14] Patent: WO2005/123724, 2005, A1,
[15] Letters in Drug Design and Discovery, 2018, vol. 16, # 2, p. 111 - 118
  • 4
  • [ 201230-82-2 ]
  • [ 78704-49-1 ]
  • [ 14548-38-0 ]
Reference: [1] Journal of Organic Chemistry, 1993, vol. 58, # 20, p. 5386 - 5392
  • 5
  • [ 52085-96-8 ]
  • [ 14548-38-0 ]
YieldReaction ConditionsOperation in experiment
84% at 20 - 45℃; for 4.5 h; In a 250-mL four-necked flask equipped with a tail suction, 120 g of anhydrous hexafluoroisopropanol and 1 g of anhydrous ferric chloride were added; at 20° C., 20 g of p-chlorophenylpropionyl chloride was slowly added dropwise; The reaction was incubated at 25°C for 3 hours, and the temperature was raised to 45°C for 1.5 hours until the acyl chloride was completely converted and no hydrogen chloride tail gas was released. After cooling to room temperature, the solvent was degassed under negative pressure and reconstituted with 15 ml of methanol.Crystallization gave 13.7 g of 6-chloro-1-indanone in a yield of 84percent.
Reference: [1] Patent: CN107673956, 2018, A, . Location in patent: Paragraph 0023; 0024
[2] Chemische Berichte, 1942, vol. 75, p. 1730,1735
[3] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 5, p. 1333 - 1336
[4] Journal of Medicinal Chemistry, 2003, vol. 46, # 3, p. 399 - 408
[5] Patent: WO2005/77907, 2005, A1, . Location in patent: Page/Page column 19; 36-37
[6] Journal of Medicinal Chemistry, 2008, vol. 51, # 3, p. 449 - 469
[7] ChemMedChem, 2010, vol. 5, # 4, p. 552 - 558
[8] Patent: WO2005/123724, 2005, A1, . Location in patent: Page/Page column 48; 92
  • 6
  • [ 69975-65-1 ]
  • [ 14548-38-0 ]
Reference: [1] Bioorganic and medicinal chemistry, 2003, vol. 11, # 2, p. 251 - 263
[2] Chemistry - A European Journal, 2015, vol. 21, # 37, p. 13052 - 13057
  • 7
  • [ 1313762-44-5 ]
  • [ 14548-38-0 ]
Reference: [1] Chemical Communications, 2011, vol. 47, # 23, p. 6635 - 6637
  • 8
  • [ 104-88-1 ]
  • [ 14548-38-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 5, p. 1333 - 1336
[2] Letters in Drug Design and Discovery, 2014, vol. 11, # 5, p. 578 - 585
[3] Letters in Drug Design and Discovery, 2018, vol. 16, # 2, p. 111 - 118
  • 9
  • [ 1615-02-7 ]
  • [ 14548-38-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 5, p. 1333 - 1336
[2] Patent: WO2017/150904, 2017, A1,
  • 10
  • [ 174265-12-4 ]
  • [ 14548-38-0 ]
Reference: [1] Chemical Communications, 2011, vol. 47, # 23, p. 6635 - 6637
  • 11
  • [ 1313762-49-0 ]
  • [ 14548-38-0 ]
Reference: [1] Chemical Communications, 2011, vol. 47, # 23, p. 6635 - 6637
  • 12
  • [ 14495-51-3 ]
  • [ 14548-38-0 ]
Reference: [1] Chemical Communications, 2011, vol. 47, # 23, p. 6635 - 6637
  • 13
  • [ 7560-44-3 ]
  • [ 14548-38-0 ]
Reference: [1] Chemical Communications, 2013, vol. 49, # 33, p. 3470 - 3472
  • 14
  • [ 50561-69-8 ]
  • [ 14548-38-0 ]
Reference: [1] Chemical Communications, 2013, vol. 49, # 33, p. 3470 - 3472
  • 15
  • [ 83-33-0 ]
  • [ 14548-38-0 ]
Reference: [1] Chemistry - A European Journal, 2015, vol. 21, # 37, p. 13052 - 13057
  • 16
  • [ 24623-24-3 ]
  • [ 14548-38-0 ]
Reference: [1] Chemistry - A European Journal, 2015, vol. 21, # 37, p. 13052 - 13057
  • 17
  • [ 37556-13-1 ]
  • [ 14548-38-0 ]
Reference: [1] Archiv der Pharmazie, 1975, vol. 308, # 2, p. 94 - 109
  • 18
  • [ 107-94-8 ]
  • [ 108-90-7 ]
  • [ 15115-59-0 ]
  • [ 14548-38-0 ]
Reference: [1] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 16, p. 687
[2] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 16, p. 687
  • 19
  • [ 107-94-8 ]
  • [ 7446-70-0 ]
  • [ 108-90-7 ]
  • [ 15115-59-0 ]
  • [ 14548-38-0 ]
Reference: [1] Patent: US1754031, 1927, ,
[2] Patent: US1754031, 1927, ,
[3] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 16, p. 687
  • 20
  • [ 2019-34-3 ]
  • [ 7664-93-9 ]
  • [ 14548-38-0 ]
Reference: [1] Chemische Berichte, 1892, vol. 25, p. 2115
  • 21
  • [ 14548-38-0 ]
  • [ 3970-51-2 ]
Reference: [1] Journal of Chemical Research, 2010, # 6, p. 325 - 329
[2] Bulletin de la Societe Chimique de France, 1973, p. 3096 - 3099
[3] Patent: WO2009/23754, 2009, A1,
[4] Journal of Medicinal Chemistry, 2016, vol. 59, # 19, p. 8812 - 8829
  • 22
  • [ 14548-38-0 ]
  • [ 89-20-3 ]
Reference: [1] Chemische Berichte, 1892, vol. 25, p. 2115
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 14548-38-0 ]

Aryls

Chemical Structure| 25017-08-7

[ 25017-08-7 ]

1-(4-Chlorophenyl)pentan-1-one

Similarity: 0.98

Chemical Structure| 1889-71-0

[ 1889-71-0 ]

Benzyl 4-chlorophenyl ketone

Similarity: 0.98

Chemical Structure| 6332-83-8

[ 6332-83-8 ]

2-(4-Chlorophenyl)acetophenone

Similarity: 0.98

Chemical Structure| 7295-50-3

[ 7295-50-3 ]

1-(4-Chlorophenyl)hexan-1-one

Similarity: 0.98

Chemical Structure| 15115-59-0

[ 15115-59-0 ]

4-Chloro-2,3-dihydroinden-1-one

Similarity: 0.95

Chlorides

Chemical Structure| 25017-08-7

[ 25017-08-7 ]

1-(4-Chlorophenyl)pentan-1-one

Similarity: 0.98

Chemical Structure| 1889-71-0

[ 1889-71-0 ]

Benzyl 4-chlorophenyl ketone

Similarity: 0.98

Chemical Structure| 6332-83-8

[ 6332-83-8 ]

2-(4-Chlorophenyl)acetophenone

Similarity: 0.98

Chemical Structure| 7295-50-3

[ 7295-50-3 ]

1-(4-Chlorophenyl)hexan-1-one

Similarity: 0.98

Chemical Structure| 15115-59-0

[ 15115-59-0 ]

4-Chloro-2,3-dihydroinden-1-one

Similarity: 0.95

Ketones

Chemical Structure| 25017-08-7

[ 25017-08-7 ]

1-(4-Chlorophenyl)pentan-1-one

Similarity: 0.98

Chemical Structure| 1889-71-0

[ 1889-71-0 ]

Benzyl 4-chlorophenyl ketone

Similarity: 0.98

Chemical Structure| 6332-83-8

[ 6332-83-8 ]

2-(4-Chlorophenyl)acetophenone

Similarity: 0.98

Chemical Structure| 7295-50-3

[ 7295-50-3 ]

1-(4-Chlorophenyl)hexan-1-one

Similarity: 0.98

Chemical Structure| 15115-59-0

[ 15115-59-0 ]

4-Chloro-2,3-dihydroinden-1-one

Similarity: 0.95